For meningiomas, which of the following is NOT included in the immunohistochemistry panel?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Prepare for the CMID Test. Study with flashcards and multiple choice questions, each question contains hints and explanations. Get ready for your exam with confidence!

Multiple Choice

For meningiomas, which of the following is NOT included in the immunohistochemistry panel?

Explanation:
Immunohistochemistry for meningioma aims to confirm meningothelial origin and distinguish it from glial tumors. Meningiomas characteristically express epithelial membrane antigen (EMA) strongly and show diffuse vimentin positivity, reflecting their arachnoid-cell lineage. S-100 can be variably positive as well. In contrast, GFAP is a marker of glial tumors (such as astrocytomas) and is typically negative in meningiomas, helping to separate them from glial neoplasms. Because GFAP does not support a meningioma diagnosis and isn’t needed to confirm it, it’s not part of the routine panel.

Immunohistochemistry for meningioma aims to confirm meningothelial origin and distinguish it from glial tumors. Meningiomas characteristically express epithelial membrane antigen (EMA) strongly and show diffuse vimentin positivity, reflecting their arachnoid-cell lineage. S-100 can be variably positive as well. In contrast, GFAP is a marker of glial tumors (such as astrocytomas) and is typically negative in meningiomas, helping to separate them from glial neoplasms. Because GFAP does not support a meningioma diagnosis and isn’t needed to confirm it, it’s not part of the routine panel.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy